Allogeneic CAR-NK cell therapy in R/R AML/MDS

Insights into NKG2D-targeting CAR-T cells in R/R AMLПодробнее

Allogenic NKX101 in r/r AMLПодробнее

NKG2D CARs for R/R AML and MDSПодробнее

NKG2D-based CAR-T in R/R AML and MDSПодробнее

Targetting cancer with allogeneic NK cell therapiesПодробнее

An introduction to CAR-T and CAR-NK cell therapy developmentПодробнее

The emergence of novel antibodies, CAR-T and CAR-NK therapies in AMLПодробнее

Nkarta - Allogeneic CAR Natural Killer (NK) Cell TherapyПодробнее

Phase I study of CD123 NK cell engager SAR443579 in R/R AML, B-ALL or HR-MDSПодробнее

What is Allogeneic NK Cell Therapy?Подробнее

CAR-NKs for B cell malignanciesПодробнее

CAR NK therapy: An experimental immunotherapy treatment for blood cancersПодробнее

Design of a Phase I trial of allogeneic anti-CD123 CAR T-cells in R/R AMLПодробнее

Investigating allogeneic iNKT cell therapyПодробнее

Update on CAR-NK cell therapy work at MD AndersonПодробнее

Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigenПодробнее

CAR T Cell Therapy in MDS/AMLПодробнее

NKG2D CAR-T cell therapy in AML/MDSПодробнее

Challenges in developing CAR-T therapy for AMLПодробнее